Nyheter
Biostock (extern källa)
Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”
Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation radioconjugates to treat cancer.
The deal showcases rising interest in the field of radiopharmaceuticals.